Replies to post #2155 on SELLAS Life Sciences Group Inc (SLS)

[TheFinalCD]

1.27

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level $SLS https://t.co/bQBsEQo7jc

— Health Stocks News (@health_stocks) May 1, 2024